Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17600703 | 1.00 | L3MBTL1 (0.53) | L3MBTL1ABL1RIN1SPHK2POLB | |
| SCHEMBL25793189 | 0.88 | L3MBTL1 (0.51) | L3MBTL1EPHX2MEN1KMT2ASCD5 | |
| SCHEMBL25796211 | 0.81 | L3MBTL1 (0.53) | L3MBTL1EPHX2MEN1KMT2ARIPK1 | |
| SCHEMBL28292565 | 0.80 | L3MBTL1 (0.49) | L3MBTL1NTRK1CYP3A4CHRNB2CHRNB4 | |
| SCHEMBL8636150 | 0.80 | ABL1 (0.43) | L3MBTL1ABL1RIN1SPHK2POLB | |
| SCHEMBL3168186 | 0.79 | DGAT1 (0.58) | L3MBTL1EPHX2SCD5 | |
| SCHEMBL3168169 | 0.79 | DGAT1 (0.58) | L3MBTL1EPHX2SCD5 | |
| SCHEMBL4931440 | 0.78 | SPHK2 (0.64) | L3MBTL1SPHK2POLBMEN1KMT2A | |
| SCHEMBL11447207 | 0.78 | SPHK2 (0.64) | L3MBTL1SPHK2POLBMEN1KMT2A | |
| SCHEMBL4927632 | 0.78 | L3MBTL1 (0.53) | L3MBTL1SPHK2EPHX2CNR2SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| EP-2970196-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190300477-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190202782-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190010121-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOBLOGIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-01-10 | — | — | US | disclosed |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450269-B1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | L3MBTL1 3065/4885ABL1 956/4885RIN1 4625/4885 |
| US-20160083343-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | L3MBTL1 2996/4885ABL1 837/4885RIN1 4642/4885 |
| US-11053195-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | L3MBTL1 2996/4885ABL1 837/4885RIN1 4642/4885 |
| US-20190300477-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | L3MBTL1 3065/4885ABL1 956/4885RIN1 4625/4885 |
| US-20190202782-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | L3MBTL1 2996/4885ABL1 837/4885RIN1 4642/4885 |
| US-20190010121-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOBLOGIN | HBG2, HBG1, HBB | L3MBTL1 2138/4885ABL1 2747/4885RIN1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.